CRACR2A and metabolic dysfunction-associated steatotic liver disease: Our findings may contribute to a better understanding of the molecular landscape associated with Rab46, opening avenues for further investigation into the biological processes and potential therapeutic targets associated with non-alcoholic fatty liver disease.